# BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma

> **NCT05538988** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **AHS Cancer Control Alberta**

## Conditions studied

- Mycosis Fungoides

## Interventions

- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT05538988
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12
- **Primary completion:** 2025-02
- **Final completion:** 2026-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Contractual Issues
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05538988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05538988, "BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05538988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*